{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:31:03Z","timestamp":1792024263880,"version":"4.4.0"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:00:00Z","timestamp":1768003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:00:00Z","timestamp":1768003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100011576","name":"In\u00f6n\u00fc \u00dcniversitesi","doi-asserted-by":"publisher","award":["TYL-2022-3087"],"award-info":[{"award-number":["TYL-2022-3087"]}],"id":[{"id":"10.13039\/501100011576","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Histol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s10735-025-10708-9","type":"journal-article","created":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T03:32:39Z","timestamp":1768015959000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Protective effects of buloxibutid and empagliflozin on hypertension-induced cardiac and vascular injury in rats"],"prefix":"10.1007","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9018-7849","authenticated-orcid":false,"given":"Onural","family":"Ozhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0896-4990","authenticated-orcid":false,"given":"Mehmet","family":"Colak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1723-2556","authenticated-orcid":false,"given":"Elif","family":"Karaca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7949-9582","authenticated-orcid":false,"given":"Feyzi","family":"Dogru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7956-9272","authenticated-orcid":false,"given":"Zeynep","family":"Kucukakcali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1131-1878","authenticated-orcid":false,"given":"Ahmet","family":"Acet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9497-3468","authenticated-orcid":false,"given":"Hakan","family":"Parlakpinar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,10]]},"reference":[{"key":"10708_CR1","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0076-6879(84)05016-3","volume":"105","author":"H Aebi","year":"1984","unstructured":"Aebi H (1984) Catalase in vitro. Methods Enzymol 105:121\u2013126","journal-title":"Methods Enzymol"},{"key":"10708_CR2","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1016\/j.sjbs.2020.05.009","volume":"27","author":"A Ahad","year":"2020","unstructured":"Ahad A, Raish M, Jardan YB, Alam M, Al-Mohizea A, Al-Jenoobi F (2020) Potential pharmacodynamic and pharmacokinetic interactions of Nigella Sativa and Trigonella Foenum-graecum with losartan in L-NAME induced hypertensive rats. Saudi J Biol Sci 27:2544\u20132550","journal-title":"Saudi J Biol Sci"},{"key":"10708_CR3","doi-asserted-by":"publisher","first-page":"bqab157","DOI":"10.1210\/endocr\/bqab157","volume":"162","author":"M Ala","year":"2021","unstructured":"Ala M (2021) SGLT2 inhibition for cardiovascular diseases, chronic kidney disease and NAFLD. Endocrinology 162(12):bqab157","journal-title":"Endocrinology"},{"issue":"4","key":"10708_CR4","doi-asserted-by":"publisher","first-page":"557","DOI":"10.3390\/clinpract12040059","volume":"12","author":"D Antwi-Amoabeng","year":"2022","unstructured":"Antwi-Amoabeng D, Sathappan S, Beutler BD, Ulanja MB, Awad M, Gullapalli N et al (2022) Association between empagliflozin use and electrocardiographic changes. Clin Pract 12(4):557\u2013564","journal-title":"Clin Pract"},{"issue":"3","key":"10708_CR5","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1161\/01.HYP.22.3.380","volume":"22","author":"J Arnal","year":"1993","unstructured":"Arnal J, Amrani A-IE, Chatellier G, M\u00e9nard Jl, Michel J (1993) Cardiac weight in hypertension induced by nitric oxide synthase blockade. Hypertension 22(3):380\u2013387","journal-title":"Hypertension"},{"issue":"9733","key":"10708_CR6","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1016\/S0140-6736(10)60407-2","volume":"375","author":"CJ Bailey","year":"2010","unstructured":"Bailey CJ, Gross JL, Pieters A, Bastien A, List JF (2010) Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 375(9733):2223\u20132233","journal-title":"Lancet"},{"issue":"6","key":"10708_CR7","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1111\/1440-1681.13075","volume":"46","author":"T Baka","year":"2019","unstructured":"Baka T, Simko F (2019) Ivabradine reversed nondipping heart rate in rats with l-NAME-induced hypertension. Clin Exp Pharmacol Physiol 46(6):607\u2013610","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10708_CR8","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1097\/00004872-199610000-00009","volume":"14","author":"J Banting","year":"1996","unstructured":"Banting J, Wiseman S, Adams M (1996) Hypertension without cardiac hypertrophy does not induce cardiac baroreflex deficit. J Hypertens 14:1209\u20131214","journal-title":"J Hypertens"},{"issue":"4","key":"10708_CR9","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1161\/01.CIR.101.4.423","volume":"101","author":"J Bartunek","year":"2000","unstructured":"Bartunek J, Weinberg E, Tajima M, Rohrbach S, Katz S, Douglas P et al (2000) Chronic N(G)-nitro-L-arginine methyl ester-induced hypertension: novel molecular adaptation to systolic load in absence of hypertrophy. Circulation 101(4):423\u2013429","journal-title":"Circulation"},{"key":"10708_CR10","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1161\/ATVBAHA.118.311339","volume":"38","author":"D Basu","year":"2018","unstructured":"Basu D, Huggins L, Scerbo D, Obunike J, Mullick A, Rothenberg P et al (2018) Mechanism of increased LDL (low-density lipoprotein) and decreased triglycerides with SGLT2 (sodium-glucose cotransporter 2) inhibition. Arterioscler Thromb Vasc Biol 38(9):2207\u20132216","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10708_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcha.2021.100725","author":"J Benham","year":"2021","unstructured":"Benham J, Booth J, Sigal R, Daskalopoulou S, Leung A, Rabi D (2021) Systematic review and meta-analysis: SGLT2 inhibitors, blood pressure and cardiovascular outcomes. IJC Heart Vasc 33:100725. https:\/\/doi.org\/10.1016\/j.ijcha.2021.100725","journal-title":"IJC Heart Vasc"},{"issue":"1","key":"10708_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12906-017-1972-0","volume":"17","author":"DC Bilanda","year":"2017","unstructured":"Bilanda DC, Dzeufiet PDD, Kouakep L, Aboubakar BFO, Tedong L, Kamtchouing P et al (2017) Bidens pilosa ethylene acetate extract can protect against L-NAME-induced hypertension on rats. BMC Complement Altern Med 17(1):479","journal-title":"BMC Complement Altern Med"},{"issue":"11","key":"10708_CR13","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1097\/00004872-199917110-00004","volume":"17","author":"J Blanc","year":"1999","unstructured":"Blanc J, Ponchon P, Laude D, Elghozi J, Jover B (1999) Blood pressure variability in established L-NAME hypertension in rats. J Hypertens 17(11):1527\u20131534","journal-title":"J Hypertens"},{"issue":"8","key":"10708_CR14","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1161\/CIRCRESAHA.116.307509","volume":"118","author":"CL Blenck","year":"2016","unstructured":"Blenck CL, Harvey PA, Reckelhoff JF, Leinwand LA (2016) The importance of biological sex and estrogen in rodent models of cardiovascular health and disease. Circ Res 118(8):1294\u20131312","journal-title":"Circ Res"},{"issue":"10","key":"10708_CR15","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1002\/ejhf.2677","volume":"24","author":"M B\u00f6hm","year":"2022","unstructured":"B\u00f6hm M, Butler J, Mahfoud F, Filippatos G, Ferreira JP, Pocock SJ et al (2022) Heart failure outcomes according to heart rate and effects of empagliflozin in patients of the EMPEROR-preserved trial. Eur J Heart Fail 24(10):1883\u20131891","journal-title":"Eur J Heart Fail"},{"key":"10708_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.vph.2022.107095","volume":"146","author":"C Bruckert","year":"2022","unstructured":"Bruckert C, Matsushita K, Mroueh A, Amissi S, Auger C, Houngue U et al (2022) Empagliflozin prevents angiotensin II-induced hypertension related micro and macrovascular endothelial cell activation and diastolic dysfunction in rats despite persistent hypertension: role of endothelial SGLT1 and 2. Vasc Pharmacol 146:107095","journal-title":"Vasc Pharmacol"},{"key":"10708_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2022.120862","volume":"307","author":"P Bugga","year":"2022","unstructured":"Bugga P, Mohammed SA, Alam MJ, Katare P, Meghwani H, Maulik SK et al (2022) Empagliflozin prohibits high-fructose diet-induced cardiac dysfunction in rats via attenuation of mitochondria-driven oxidative stress. Life Sci 307:120862","journal-title":"Life Sci"},{"issue":"3","key":"10708_CR18","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1161\/01.CIR.101.3.329","volume":"101","author":"OA Carretero","year":"2000","unstructured":"Carretero OA, Oparil S (2000) Essential hypertension. Part I: definition and etiology. Circulation 101(3):329\u2013335","journal-title":"Circulation"},{"key":"10708_CR19","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3892\/mmr.2024.13197","volume":"29","author":"B Chen","year":"2024","unstructured":"Chen B, Guo J, Ye H, Wang X, Feng Y (2024) Role and molecular mechanisms of SGLT2 inhibitors in pathological cardiac remodeling. Mol Med Rep 29:73","journal-title":"Mol Med Rep"},{"issue":"1","key":"10708_CR20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.33549\/physiolres.934497","volume":"70","author":"TY Chia","year":"2021","unstructured":"Chia TY, Murugaiyah V, Khan NA, Sattar MA, Abdulla MH, Johns EJ et al (2021) Inhibition of L-NAME-induced hypertension by combined treatment with apocynin and catalase: the role of Nox 4 expression. Physiol Res 70(1):13\u201326","journal-title":"Physiol Res"},{"issue":"8","key":"10708_CR21","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1007\/s00125-016-3977-5","volume":"59","author":"BS Chow","year":"2016","unstructured":"Chow BS, Koulis C, Krishnaswamy P, Steckelings UM, Unger T, Cooper ME et al (2016) The angiotensin II type 2 receptor agonist compound 21 is protective in experimental diabetes-associated atherosclerosis. Diabetologia 59(8):1778\u20131790","journal-title":"Diabetologia"},{"key":"10708_CR22","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/3981790","volume":"2016","author":"SY Dai","year":"2016","unstructured":"Dai SY, Zhang YP, Peng W, Shen Y, He JJ (2016) Central infusion of angiotensin II type 2 receptor agonist compound 21 attenuates DOCA\/NaCl-induced hypertension in female rats. Oxid Med Cell Longev 2016:3981790","journal-title":"Oxid Med Cell Longev"},{"key":"10708_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2022.109245","volume":"726","author":"GL Ellman","year":"2022","unstructured":"Ellman GL (2022) Reprint of: tissue sulfhydryl groups. Arch Biochem Biophys 726:109245","journal-title":"Arch Biochem Biophys"},{"issue":"4","key":"10708_CR24","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.clinbiochem.2003.11.015","volume":"37","author":"O Erel","year":"2004","unstructured":"Erel O (2004) A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin Biochem 37(4):277\u2013285","journal-title":"Clin Biochem"},{"issue":"12","key":"10708_CR25","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.clinbiochem.2005.08.008","volume":"38","author":"O Erel","year":"2005","unstructured":"Erel O (2005) A new automated colorimetric method for measuring total oxidant status. Clin Biochem 38(12):1103\u20131111","journal-title":"Clin Biochem"},{"issue":"5","key":"10708_CR26","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1080\/10520295.2023.2187461","volume":"98","author":"N Ermis","year":"2023","unstructured":"Ermis N, Ulutas Z, Ozhan O, Yildiz A, Vardi N, Colak C et al (2023) Angiotensin II type 2 receptor agonist treatment of doxorubicin induced heart failure. Biotech Histochem 98(5):326\u2013335","journal-title":"Biotech Histochem"},{"issue":"10","key":"10708_CR27","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1093\/ajh\/hpu044","volume":"27","author":"J Gao","year":"2014","unstructured":"Gao J, Zucker I, Gao L (2014) Activation of central angiotensin type 2 receptors by compound 21 improves arterial baroreflex sensitivity in rats with heart failure. Am J Hypertens 27(10):1248\u20131256","journal-title":"Am J Hypertens"},{"key":"10708_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.metop.2020.100039","volume":"7","author":"V Garg","year":"2020","unstructured":"Garg V, Verma S, Connelly KA, Yan AT, Sikand A, Garg A et al (2020) Does empagliflozin modulate the autonomic nervous system among individuals with type 2 diabetes and coronary artery disease? The EMPA-HEART CardioLink-6 Holter analysis. Metab Open 7:100039","journal-title":"Metab Open"},{"issue":"5","key":"10708_CR29","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1210\/endo.138.5.5236","volume":"138","author":"CH Gelband","year":"1997","unstructured":"Gelband CH, Zhu M, Lu D, Reagan LP, Fluharty SJ, Posner P et al (1997) Functional interactions between neuronal AT1 and AT2 receptors. Endocrinology 138(5):2195\u20132198","journal-title":"Endocrinology"},{"issue":"3","key":"10708_CR30","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3831\/KPI.2019.22.021","volume":"22","author":"I Hamounpeima","year":"2019","unstructured":"Hamounpeima I, Hosseini M, Mohebbati R, Shafei MN (2019) Effect of hydroalcoholic extract of Ribes khorasanicum on acute hypertension induced by L-NAME in rat. J Pharmacopuncture 22(3):160\u2013165","journal-title":"J Pharmacopuncture"},{"issue":"10","key":"10708_CR31","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1080\/14656566.2020.1751815","volume":"21","author":"LY Herat","year":"2020","unstructured":"Herat LY, Matthews VB, Magno AL, Kiuchi MG, Carnagarin R, Schlaich MP (2020) An evaluation of empagliflozin and it\u2019s applicability to hypertension as a therapeutic option. Expert Opin Pharmacother 21(10):1157\u20131166","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"10708_CR32","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1093\/rheumatology\/keac426","volume":"62","author":"AL Herrick","year":"2023","unstructured":"Herrick AL, Batta R, Overbeck K, Raud J, Manning J, Murray A et al (2023) A phase 2 trial investigating the effects of the angiotensin II type 2 receptor agonist C21 in systemic sclerosis-related Raynaud\u2019s. Rheumatology (Oxford) 62(2):824\u2013828","journal-title":"Rheumatology (Oxford)"},{"key":"10708_CR33","doi-asserted-by":"publisher","first-page":"103149","DOI":"10.1016\/j.cpcardiol.2025.103149","volume":"50","author":"P Karakasis","year":"2025","unstructured":"Karakasis P, Theofilis P, Vlachakis P, Apostolos A, Milaras N, Ktenopoulos N et al (2025) SGLT2 inhibitors and cardiac fibrosis: a comprehensive review. Curr Probl Cardiol 50:103149","journal-title":"Curr Probl Cardiol"},{"issue":"Pt A","key":"10708_CR34","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.phrs.2017.07.008","volume":"125","author":"E Kaschina","year":"2017","unstructured":"Kaschina E, Namsolleck P, Unger T (2017) AT2 receptors in cardiovascular and renal diseases. Pharmacol Res 125(Pt A):39\u201347","journal-title":"Pharmacol Res"},{"issue":"7","key":"10708_CR35","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1111\/j.1476-5381.2010.00872.x","volume":"160","author":"C Kilkenny","year":"2010","unstructured":"Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG (2010) Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160(7):1577\u20131579","journal-title":"Br J Pharmacol"},{"issue":"12","key":"10708_CR36","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1038\/s41440-019-0326-3","volume":"42","author":"S Kim","year":"2019","unstructured":"Kim S, Jo CH, Kim GH (2019) Effects of empagliflozin on nondiabetic salt-sensitive hypertension in uninephrectomized rats. Hypertens Res 42(12):1905\u20131915","journal-title":"Hypertens Res"},{"issue":"8","key":"10708_CR37","volume":"15","author":"P Kodela","year":"2023","unstructured":"Kodela P, Okeke M, Guntuku S, Lingamsetty SSP, Slonovschi E (2023) Management of hypertension with non-pharmacological interventions: a narrative review. Cureus 15(8):e43022","journal-title":"Cureus"},{"issue":"8","key":"10708_CR38","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1159\/000516213","volume":"52","author":"P Kolkhof","year":"2021","unstructured":"Kolkhof P, Hartmann E, Freyberger A, Pavkovic M, Mathar I, Sandner P et al (2021) Effects of finerenone combined with empagliflozin in a model of hypertension-induced end-organ damage. Am J Nephrol 52(8):642\u2013652","journal-title":"Am J Nephrol"},{"issue":"4","key":"10708_CR39","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1080\/10641960902977924","volume":"31","author":"J Lee","year":"2009","unstructured":"Lee J, Cho HS, Park S, Kim WK (2009) Regular exercise produced cardioprotective effects on rat\u2019s heart with hypertension induced by L-NAME administration. Clin Exp Hypertens 31(4):364\u2013375","journal-title":"Clin Exp Hypertens"},{"key":"10708_CR40","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12933-019-0816-2","volume":"18","author":"C Li","year":"2019","unstructured":"Li C, Zhang J, Xue M, Li X, Han F, Liu X et al (2019) SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovasc Diabetol 18:15","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"10708_CR41","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","volume":"5","author":"GD Lopaschuk","year":"2020","unstructured":"Lopaschuk GD, Verma S (2020) Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review. JACC Basic Transl Sci 5(6):632\u2013644","journal-title":"JACC Basic Transl Sci"},{"key":"10708_CR42","first-page":"632","volume":"5","author":"G Lopaschuk","year":"2020","unstructured":"Lopaschuk G, Verma S (2020) Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors. JACC: Basic Transl Sci 5:632\u2013644","journal-title":"JACC: Basic Transl Sci"},{"issue":"66","key":"10708_CR43","first-page":"4402","volume":"60","author":"T Maher","year":"2022","unstructured":"Maher T, Ganslandt C, Batta R, Tornling G, Bengtsson T, Pophale H et al (2022) Interim results from AIR, an open-label, single arm, 36-week ph 2 trial of C21 in subjects with idiopathic pulmonary fibrosis. Eur Respirat J 60(66):4402","journal-title":"Eur Respirat J"},{"key":"10708_CR44","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/5349398","author":"M Majz\u00fanov\u00e1","year":"2019","unstructured":"Majz\u00fanov\u00e1 M, Majz\u00fanov\u00e1 M, Kvandov\u00e1 M, Berenyiova A, Balis P, Dovinov\u00e1 I et al (2019) Chronic NOS inhibition affects oxidative state and antioxidant response differently in the kidneys of young normotensive and hypertensive rats. Oxid Med Cell Longev 2019:5349398. https:\/\/doi.org\/10.1155\/2019\/5349398","journal-title":"Oxid Med Cell Longev"},{"issue":"6","key":"10708_CR45","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1161\/HYPERTENSIONAHA.116.07703","volume":"68","author":"G Mancia","year":"2016","unstructured":"Mancia G, Cannon CP, Tikkanen I, Zeller C, Ley L, Woerle HJ et al (2016) Impact of Empagliflozin on blood pressure in patients with type 2 diabetes mellitus and hypertension by background antihypertensive medication. Hypertension 68(6):1355\u20131364","journal-title":"Hypertension"},{"key":"10708_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/nu10101549","author":"P Maneesai","year":"2018","unstructured":"Maneesai P, Bunbupha S, Potue P, Berkban T, Kukongviriyapan U, Kukongviriyapan V et al (2018) Hesperidin prevents nitric oxide deficiency-induced cardiovascular remodeling in rats via suppressing TGF-\u03b21 and MMPs protein expression. Nutrients 10(10):1549. https:\/\/doi.org\/10.3390\/nu10101549","journal-title":"Nutrients"},{"key":"10708_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20153775","author":"C Meza","year":"2019","unstructured":"Meza C, La Favor J, Kim D-H, Hickner R (2019) Endothelial dysfunction: is there a hyperglycemia-induced imbalance of NOX and NOS? Int J Mol Sci 20(15):3775. https:\/\/doi.org\/10.3390\/ijms20153775","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10708_CR48","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/0003-2697(78)90342-1","volume":"86","author":"M Mihara","year":"1978","unstructured":"Mihara M, Uchiyama M (1978) Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. Anal Biochem 86(1):271\u2013278","journal-title":"Anal Biochem"},{"key":"10708_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2019.05.020","volume":"186","author":"KM Mirabito Colafella","year":"2019","unstructured":"Mirabito Colafella KM, Bov\u00e9e DM, Danser AHJ (2019) The renin-angiotensin-aldosterone system and its therapeutic targets. Exp Eye Res 186:107680","journal-title":"Exp Eye Res"},{"key":"10708_CR50","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1007\/BF00788911","volume":"91","author":"H Moreno","year":"1996","unstructured":"Moreno H, Metze K, Bento A, Antunes E, Zatz R, Nucci G (1996) Chronic nitric oxide inhibition as a model of hypertensive heart muscle disease. Basic Res Cardiol 91:248\u2013255","journal-title":"Basic Res Cardiol"},{"issue":"4","key":"10708_CR51","first-page":"1249","volume":"46","author":"E Mutlu","year":"2016","unstructured":"Mutlu E, Ilhan S, Onat E, Kara M, Sahna E (2016) The effects of novokinin, an AT2 agonist, on blood pressure, vascular responses, and levels of ADMA, NADPH oxidase, and Rho kinase in hypertension induced by NOS inhibition and salt. Turk J Med Sci 46(4):1249\u20131257","journal-title":"Jtjoms"},{"issue":"1","key":"10708_CR52","first-page":"25","volume":"100","author":"MF O'Rourke","year":"2009","unstructured":"O\u2019Rourke MF, Namasivayam M, Adji A (2009) Treatment of hypertension in patients 80 years of age or older. Minerva Med 100(1):25\u201338","journal-title":"Minerva Med"},{"issue":"4","key":"10708_CR53","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/fcp.12599","volume":"35","author":"O Ozhan","year":"2021","unstructured":"Ozhan O, Parlakpinar H, Acet A (2021) Comparison of the effects of losartan, captopril, angiotensin II type 2 receptor agonist compound 21, and MAS receptor agonist AVE 0991 on myocardial ischemia-reperfusion necrosis in rats. Fundam Clin Pharmacol 35(4):669\u2013680","journal-title":"Fundam Clin Pharmacol"},{"issue":"1","key":"10708_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-025-01938-w","volume":"25","author":"O Ozhan","year":"2025","unstructured":"Ozhan O, Colak M, Karaca E, Dogru F, Kucukakcali Z, Acet A et al (2025) Renoprotective effects of compound 21 and empagliflozin in L-Name-induced hypertensive rats. BMC Urol 25(1):239","journal-title":"BMC Urol"},{"issue":"9","key":"10708_CR55","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.transproceed.2025.02.045","volume":"57","author":"KE \u00d6ztop","year":"2025","unstructured":"\u00d6ztop KE, Can Y, \u0130slam M, Demirci T, \u00c7akar GC, F\u0131rat N et al (2025) Impact of empagliflozin on cardiac arrhythmias and heart rate variability in kidney transplant recipients. Transpl Proc 57(9):1731\u20131735","journal-title":"Transpl Proc"},{"issue":"1","key":"10708_CR56","first-page":"158","volume":"70","author":"DE Paglia","year":"1967","unstructured":"Paglia DE, Valentine WN (1967) Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 70(1):158\u2013169","journal-title":"J Lab Clin Med"},{"key":"10708_CR57","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00028.2018","author":"G Paradies","year":"2018","unstructured":"Paradies G, Paradies V, Ruggiero F, Petrosillo G (2018) Mitochondrial bioenergetics and cardiolipin alterations in myocardial ischemia-reperfusion injury: implications for pharmacological cardioprotection. Am J Physiol Heart Circ Physiol 315(5):H1341-H1352. https:\/\/doi.org\/10.1152\/ajpheart.00028.2018","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"2","key":"10708_CR58","first-page":"172","volume":"3","author":"S Parasuraman","year":"2012","unstructured":"Parasuraman S, Raveendran R (2012) Measurement of invasive blood pressure in rats. J Pharmacol Pharmacother 3(2):172\u2013177","journal-title":"J Pharmacol Pharmacother"},{"issue":"1","key":"10708_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-021-01252-3","volume":"20","author":"SH Park","year":"2021","unstructured":"Park SH, Belcastro E, Hasan H, Matsushita K, Marchandot B, Abbas M et al (2021) Angiotensin II-induced upregulation of SGLT1 and 2 contributes to human microparticle-stimulated endothelial senescence and dysfunction: protective effect of gliflozins. Cardiovasc Diabetol 20(1):65","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"10708_CR60","first-page":"353","volume":"48","author":"O Pech\u00e1nov\u00e1","year":"1999","unstructured":"Pech\u00e1nov\u00e1 O, Bern\u00e1tov\u00e1 I, Pelouch V, Bab\u00e1l P (1999) L-NAME-induced protein remodeling and fibrosis in the rat heart. Physiol Res 48(5):353\u2013362","journal-title":"Physiol Res"},{"key":"10708_CR61","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1093\/cvr\/cvae047","volume":"120","author":"A Preda","year":"2024","unstructured":"Preda A, Montecucco F, Carbone F, Camici G, L\u00fcscher T, Kraler S et al (2024) SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits. Cardiovasc Res 120:443\u2013460","journal-title":"Cardiovasc Res"},{"key":"10708_CR62","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3389\/fphys.2018.00180","volume":"9","author":"A Rathinasabapathy","year":"2018","unstructured":"Rathinasabapathy A, Horowitz A, Horton K, Kumar A, Gladson S, Unger T et al (2018) The selective angiotensin II type 2 receptor agonist, compound 21, attenuates the progression of lung fibrosis and pulmonary hypertension in an experimental model of bleomycin-induced lung injury. Front Physiol 9:180","journal-title":"Front Physiol"},{"issue":"2","key":"10708_CR63","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1161\/HYPERTENSIONAHA.111.180158","volume":"59","author":"A Rehman","year":"2012","unstructured":"Rehman A, Leibowitz A, Yamamoto N, Rautureau Y, Paradis P, Schiffrin EL (2012) Angiotensin type 2 receptor agonist compound 21 reduces vascular injury and myocardial fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension (Dallas, Tex\u202f: 1979) 59(2):291\u2013299","journal-title":"Hypertension (Dallas, Tex : 1979)"},{"issue":"4","key":"10708_CR64","doi-asserted-by":"publisher","first-page":"H523","DOI":"10.1152\/ajpheart.00386.2021","volume":"322","author":"V Reverte","year":"2022","unstructured":"Reverte V, Rodriguez F, Oltra L, Moreno JM, Llin\u00e1s MT, Shea CM et al (2022) SGLT2 inhibition potentiates the cardiovascular, renal, and metabolic effects of sGC stimulation in hypertensive rats with prolonged exposure to high-fat diet. Am J Physiol Heart Circ Physiol 322(4):H523\u2013H536","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10708_CR65","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23073651","author":"T Salvatore","year":"2022","unstructured":"Salvatore T, Galiero R, Caturano A, Rinaldi L, Di Martino A, Albanese G et al (2022) An overview of the cardiorenal protective mechanisms of SGLT2 inhibitors. Int J Mol Sci23(7):3651. https:\/\/doi.org\/10.3390\/ijms23073651","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10708_CR66","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1111\/bph.13063","volume":"173","author":"AK Sampson","year":"2016","unstructured":"Sampson AK, Irvine JC, Shihata WA, Dragoljevic D, Lumsden N, Huet O et al (2016) Compound 21, a selective agonist of angiotensin AT2 receptors, prevents endothelial inflammation and leukocyte adhesion in vitro and in vivo. Br J Pharmacol 173(4):729\u2013740","journal-title":"Br J Pharmacol"},{"issue":"9","key":"10708_CR67","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1017\/S0007114515003086","volume":"114","author":"M Saravanakumar","year":"2015","unstructured":"Saravanakumar M, Raja B, Manivannan J, Silambarasan T, Prahalathan P, Kumar S et al (2015) Oral administration of veratric acid, a constituent of vegetables and fruits, prevents cardiovascular remodelling in hypertensive rats: a functional evaluation. Br J Nutr 114(9):1385\u20131394","journal-title":"Br J Nutr"},{"issue":"10","key":"10708_CR68","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/S0026-0495(98)90323-7","volume":"47","author":"JS Striffler","year":"1998","unstructured":"Striffler JS, Bhathena SJ, Michaelis OEt, Campbell JD, Hansen CT, Scalbert E et al (1998) Long-term effects of perindopril on metabolic parameters and the heart in the spontaneously hypertensive\/NIH-corpulent rat with non-insulin-dependent diabetes mellitus and hypertension. Metabolism 47(10):1199\u20131204","journal-title":"Metabolism"},{"key":"10708_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2020.109825","volume":"77","author":"S Sukhanov","year":"2021","unstructured":"Sukhanov S, Higashi Y, Yoshida T, Mummidi S, Aroor AR, Jeffrey Russell J et al (2021) The SGLT2 inhibitor Empagliflozin attenuates interleukin-17A-induced human aortic smooth muscle cell proliferation and migration by targeting TRAF3IP2\/ROS\/NLRP3\/Caspase-1-dependent IL-1\u03b2 and IL-18 secretion. Cell Signal 77:109825","journal-title":"Cell Signal"},{"issue":"3","key":"10708_CR70","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1093\/clinchem\/34.3.497","volume":"34","author":"Y Sun","year":"1988","unstructured":"Sun Y, Oberley LW, Li Y (1988) A simple method for clinical assay of superoxide dismutase. Clin Chem 34(3):497\u2013500","journal-title":"Clin Chem"},{"key":"10708_CR71","doi-asserted-by":"publisher","DOI":"10.3390\/jcdd9080276","author":"MA Talle","year":"2022","unstructured":"Talle MA, Ngarande E, Doubell AF, Herbst PG (2022) Cardiac complications of hypertensive emergency: classification, diagnosis and management challenges. J Cardiovasc Dev Dis 9(8):276. https:\/\/doi.org\/10.3390\/jcdd9080276","journal-title":"J Cardiovasc Dev Dis"},{"issue":"1","key":"10708_CR72","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.bjorl.2021.07.001","volume":"88","author":"M Tan","year":"2022","unstructured":"Tan M, Toplu Y, Varan E, Sapmaz E, \u00d6zhan O, Parlakp\u0131nar H et al (2022) The effect of genistein on cisplatin induced ototoxicity and oxidative stress. Braz J Otorhinolaryngol 88(1):105\u2013111","journal-title":"Braz J Otorhinolaryngol"},{"key":"10708_CR73","doi-asserted-by":"publisher","first-page":"800490","DOI":"10.3389\/fphar.2022.800490","volume":"13","author":"J Tang","year":"2022","unstructured":"Tang J, Ye L, Yan Q, Zhang X, Wang L (2022) Effects of sodium-glucose cotransporter 2 inhibitors on water and sodium metabolism. Front Pharmacol 13:800490","journal-title":"Front Pharmacol"},{"key":"10708_CR74","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24087478","author":"G Tornling","year":"2023","unstructured":"Tornling G, Batta R, Salvail D, Raud J, Denton CP (2023) Effects of the oral angiotensin II type 2 receptor agonist C21 in Sugen-hypoxia induced pulmonary hypertension in rats. Int J Mol Sci24(8):7478. https:\/\/doi.org\/10.3390\/ijms24087478","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10708_CR75","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s12012-020-09590-6","volume":"21","author":"Z Ulutas","year":"2021","unstructured":"Ulutas Z, Ermis N, Ozhan O, Parlakpinar H, Vardi N, Ates B et al (2021) The protective effects of compound 21 and valsartan in isoproterenol-induced myocardial injury in rats. Cardiovasc Toxicol 21(1):17\u201328","journal-title":"Cardiovasc Toxicol"},{"issue":"3","key":"10708_CR76","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1161\/HYPERTENSIONAHA.112.196022","volume":"60","author":"K Verdonk","year":"2012","unstructured":"Verdonk K, Durik M, Abd-Alla N, Batenburg WW, van den Bogaerdt AJ, van Veghel R et al (2012) Compound 21 induces vasorelaxation via an endothelium- and angiotensin II type 2 receptor-independent mechanism. Hypertension 60(3):722\u2013729","journal-title":"Hypertension"},{"issue":"4","key":"10708_CR77","first-page":"535","volume":"70","author":"S Vrankova","year":"2019","unstructured":"Vrankova S, Zemancikova A, Torok J, Pechanova O (2019) Effect of low dose L-NAME pretreatment on nitric oxide\/reactive oxygen species balance and vasoactivity in L-NAME\/salt-induced hypertensive rats. J Physiol Pharmacol 70(4):535\u2013544","journal-title":"J Physiol Pharmacol"},{"issue":"7","key":"10708_CR78","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1093\/cvr\/22.7.447","volume":"22","author":"MJ Walker","year":"1988","unstructured":"Walker MJ, Curtis MJ, Hearse DJ, Campbell RW, Janse MJ, Yellon DM et al (1988) The Lambeth conventions: guidelines for the study of arrhythmias in ischaemia infarction, and reperfusion. Cardiovasc Res 22(7):447\u2013455","journal-title":"Cardiovasc Res"},{"issue":"7","key":"10708_CR79","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1080\/10641963.2017.1306539","volume":"39","author":"Y Wang","year":"2017","unstructured":"Wang Y, Zhang F, Liu Y, Yin S, Pang X, Li Z et al (2017) Nebivolol alleviates aortic remodeling through eNOS upregulation and inhibition of oxidative stress in l-NAME-induced hypertensive rats. Clin Exp Hypertens 39(7):628\u2013639","journal-title":"Clin Exp Hypertens"},{"key":"10708_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.05.050","author":"C Wang","year":"2020","unstructured":"Wang C, Kawakami-Mori F, Kang L, Ayuzawa N, Ogura S, Koid S et al (2020) Low dose L-NAME induces salt sensitivity associated with sustained increased blood volume and sodium-chloride cotransporter activity in rodents. Kidney Int98(5):1242\u20131252. https:\/\/doi.org\/10.1016\/j.kint.2020.05.050","journal-title":"Kidney Int"},{"key":"10708_CR81","first-page":"1","volume":"32","author":"JH Waterborg","year":"1994","unstructured":"Waterborg JH, Matthews HR (1994) The Lowry method for protein quantitation. Methods Mol Biol (Clifton, NJ) 32:1\u20134","journal-title":"Methods Mol Biol (Clifton, NJ)"},{"issue":"1","key":"10708_CR82","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/HJH.0000000000000065","volume":"32","author":"MA Weber","year":"2014","unstructured":"Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG et al (2014) Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens 32(1):3\u201315","journal-title":"J Hypertens"},{"issue":"6 Pt 2","key":"10708_CR83","first-page":"H2267","volume":"268","author":"A Zanchi","year":"1995","unstructured":"Zanchi A, Schaad NC, Osterheld MC, Grouzmann E, Nussberger J, Brunner HR et al (1995) Effects of chronic NO synthase inhibition in rats on renin-angiotensin system and sympathetic nervous system. Am J Physiol 268(6 Pt 2):H2267\u2013H2273","journal-title":"Am J Physiol"},{"issue":"16","key":"10708_CR84","doi-asserted-by":"publisher","DOI":"10.21037\/atm-22-3675","volume":"10","author":"X Zhu","year":"2022","unstructured":"Zhu X, Jiang R, Ying X, Li Z, Jiang P (2022) The role of ferritin and iron dextran in exacerbating preeclampsia in an L-NAME-treated rat model. Ann Transl Med 10(16):889","journal-title":"Ann Transl Med"}],"container-title":["Journal of Molecular Histology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10735-025-10708-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10735-025-10708-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10735-025-10708-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T07:03:59Z","timestamp":1772003039000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10735-025-10708-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,10]]},"references-count":84,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10708"],"URL":"https:\/\/doi.org\/10.1007\/s10735-025-10708-9","relation":{},"ISSN":["1567-2379","1567-2387"],"issn-type":[{"value":"1567-2379","type":"print"},{"value":"1567-2387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,10]]},"assertion":[{"value":"5 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The National Institutes of Health's Guide for the Care and Use of Laboratory Animals and ARRIVE criteria were followed in all experiments and procedures conducted for this work (Kilkenny et al.\n                      \n                      ). An application was made to Inonu University Faculty of Medicine Animal Experiments Local Ethics Committee for ethical approval and ethics committee permission was obtained at the meeting dated 09.11.2023 with ethical approval number 2023\/11-2.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"35"}}